Medeon Biodesign, Inc. (TPEX:6499)

Market Cap	9.31B
Revenue (ttm)	394.40M
Net Income (ttm)	-749.38M
Shares Out	92.14M
EPS (ttm)	-8.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,007,309
Average Volume	874,920
Open	101.00
Previous Close	92.00
Day's Range	101.00 - 101.00
52-Week Range	34.75 - 154.50
Beta	0.68
RSI	58.06
Earnings Date	Oct 31, 2025

About Medeon Biodesign

Medeon Biodesign, Inc. researches, develops, manufactures, and sells medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site hernia...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2012
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6499

Financial Performance

In 2024, Medeon Biodesign's revenue was 292.81 million, an increase of 49.19% compared to the previous year's 196.26 million. Losses were -805.51 million, -33.13% less than in 2023.